Castle Biosciences, Inc.
CSTL
$18.63
-$0.41-2.15%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -153.15% | -232.41% | -301.42% | -205.45% | 83.54% |
| Total Depreciation and Amortization | -123.14% | -96.43% | -80.96% | 71.08% | 74.68% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -19.49% | 66.11% | 45.49% | 37.12% | 43.21% |
| Change in Net Operating Assets | 193.09% | 196.29% | 119.13% | 24.19% | -14.01% |
| Cash from Operations | -26.51% | -0.80% | 4.56% | 53.30% | 405.97% |
| Capital Expenditure | -82.89% | -27.17% | -48.27% | -35.48% | -23.05% |
| Sale of Property, Plant, and Equipment | 95.45% | 150.00% | 235.71% | 166.67% | 69.23% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.45% | 74.05% | 78.63% | 65.19% | 12.32% |
| Cash from Investing | -20.56% | -20.40% | 0.24% | -2.27% | -0.76% |
| Total Debt Issued | -- | -- | -100.00% | -100.00% | -100.00% |
| Total Debt Repaid | -29.89% | -18.56% | -6.54% | 10.08% | 39.16% |
| Issuance of Common Stock | 8.09% | -7.52% | -40.07% | 60.35% | 58.17% |
| Repurchase of Common Stock | -45.70% | -33.04% | -66.74% | -100.50% | -104.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -72.33% | -213.37% | -194.27% | -180.70% | -179.52% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -484.64% | -114.28% | -351.69% | 67.59% | 121.15% |